The description related to agreement.

No definition available.

Name:	tffp_AgreementDescription
Namespace Prefix:	tffp_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Under a term repurchase agreement, a bank will agree to buy securities from a dealer and then resell them a short time later at a specified price.

+ References

No definition available.

+ Details

Name:	tffp_AgreementTremDescription
Namespace Prefix:	tffp_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Interst fee.

+ References

No definition available.

+ Details

Name:	tffp_InterstFee
Namespace Prefix:	tffp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	tffp_LicenseandAgreementsDetailsLineItems
Namespace Prefix:	tffp_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone fee.

+ References

No definition available.

+ Details

Name:	tffp_MilestoneFee
Namespace Prefix:	tffp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

A pre-approval is a preliminary evaluation of a potential borrower by a lender to determine whether they can be given a pre-qualification offer. Pre-approvals are generated through relationships with credit bureaus which facilitate pre-approval analysis through soft inquiries. Pre-approval marketing can provide a potential borrower with an estimated interest rate offer and a maximum principal amount.

+ References

No definition available.

+ Details

Name:	tffp_PremarketingApprovals
Namespace Prefix:	tffp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

+ Details

Name:	us-gaap_AccountsPayableCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of the fee that accompanies borrowing money under the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentFeeAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount due from parties in nontrade transactions, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(4))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_OtherReceivables
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_ITRMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_April2019Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2021Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tffp_January2022Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	tffp_AgreementAxis=tffp_MasterServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tffp_ContractManufacturingServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	tffp_AgreementAxis=tffp_MasterConsultancyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	tffp_AgreementAxis=tffp_ClinicalTrialResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Agreements (Details) - USD ($)		1 Months Ended			3 Months Ended		9 Months Ended
License and Agreements (Details) - USD ($)	Aug. 12, 2020	May 31, 2020	Jan. 31, 2020	Jan. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Nov. 24, 2019	Mar. 31, 2018
License and Agreements (Details) [Line Items]
Assignment fee											$ 100,000
Milestone payment										$ 50,000
Accounts payable due					$ 0		$ 0		$ 21,000
Recorded research and development costs					4,025,940	$ 6,339,993	14,360,293	$ 14,380,415
Pre-marketing approvals	$ 25,000,000
Interest fee							500,000
Research and development expenses					0	341,840	184,273	828,511
Other receivable					1,812,975		1,812,975		1,628,703
ITR [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					0		0		$ 0
April 2019 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					209,000	639,000	835,000	1,436,000
January 2021 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					643,000	735,000	1,223,000	1,036,000
January 2022 [Member]
License and Agreements (Details) [Line Items]
Recorded research and development costs					800,000		2,099,000
Master Services Agreement [Member]
License and Agreements (Details) [Line Items]
Agreement term, description				In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.
Recorded research and development costs					41,000		2,358,000
Master Services Agreement [Member] \| Contract Manufacturing Services [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					363,000		363,000
Recorded research and development costs						$ 0		$ 2,380,000
Master Services Agreement [Member] \| January 2021 [Member]
License and Agreements (Details) [Line Items]
Accounts payable due					$ 133,000		$ 133,000
Clinical Network Services Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description			In January 2020, TFF Australia entered into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$38,000 (US$24,000) and AUD$138,000 (US$100,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded research and development costs of approximately AUD$87,000 (US$59,000) and AUD$550,000 (US$388,000), respectively, pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$547,000 (US$402,000) and AUD$1,468,000 (US$1,113,000), respectively, pertaining to this agreement
Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]
License and Agreements (Details) [Line Items]
Agreement description		In May 2020, TFF Australia entered into an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company’s drug candidates, TFF Tac-Lac. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of September 30, 2022 and December 31, 2021, respectively. During the three and nine months ended September 30, 2022, the Company did not record any research and development costs pertaining to this agreement. During the three and nine months ended September 30, 2021, the Company recorded research and development costs of approximately AUD$119,000 (US$87,000) and AUD$565,000 (US$429,000), respectively, pertaining to this agreement.